A focused product with scalable commercial potential
Llusern’s primary commercial focus is rapid molecular UTI testing.
The Lodestar UTI testing system combines a portable analyser with unique panel of UTI tests, creating a clear device-plus-consumables opportunity across professional human clinical settings.
A device-plus-consumables model
The Lodestar DX system creates a sustainable commercial model built around the analyser and repeat use of test panels.
Lodestar DX analyser is a low cost testing platform so that high-throughput settings can run multiple analysers in parallel.
The UTI test panels are the source of recurring revenue.
Professional users in the private sector can bill against existing insurance codes. In the NHS Llusern is working with several Trusts and Board in England and Wales to build clinical evidence backed by robust health economic models.
Built around a clear diagnostic need
UTI testing is common, recurring and requires fast, accurate, professional treatment decisions. Llusern is starting with this under-served first use case because faster diagnostic information can support better-informed prescribing and more efficient care pathways.
- Clear first product focus
- High-volume diagnostic need
- Fast diagnosis has evident benefits over traditional methods
- Use within a multitude of near-patient testing settings
- Policy tailwinds around women’s health, AMR and community diagnostics
Multiple professional settings
The Lodestar UTI testing system is designed for professional users in human settings. This means that Lodestar is relevant to a range of markets where faster UTI testing can support better decision-making.
Hospitals & near-patient settings
Specialist urology clinics
Care homes & elderly care
Laboratories
Community care
Distribution channels
Designed for practical adoption
Commercial potential depends on more than the test itself. It also depends on whether the product fits real-world settings.
Lodestar DX has been designed around portability, speed and simplicity, helping make molecular UTI testing more accessible for professional users beyond central laboratory environments.
- Portable molecular testing system
- Sample-to-result in less than 40 minutes
- Requires only 10 μL of urine
- No extraction step is required
- Designed for near-patient use by professional users
- UKCA marked
Active market entry with room to scale
The Lodestar UTI testing system is already being used in selected professional healthcare settings, with NHS evaluation activity supporting its real-world evidence base.
Llusern’s next stage of growth is focused on expanding professional adoption, building commercial partnerships and developing distributor-led growth opportunities.
- Private healthcare adoption
- Professional healthcare networks
- Strategic commercial partnerships
- NHS evaluation activity
- Distributor-led growth
Starting with UTI. Built for broader diagnostic opportunity.
Llusern’s first focus is rapid molecular UTI testing. The wider ambition is to make treatment-directing diagnostics more accessible in professional settings where faster decisions matter.
Llusern has the ability to extend its menu of clinical tests, as well as explore applications within veterinary and industrial sectors.
Testimonials
Lodestar DX represents an important step in making molecular UTI testing practical at the point where treatment decisions are made.
By bringing clearer diagnostic information closer to the patient, it can support faster, better-informed decisions in real-world professional settings.
As a spinal injury patient, new symptoms feel overwhelming. Lodestar gave me instant peace of mind. I drove two hours to Reading just to avoid the usual three day wait for culture results. It is brilliant.
For months, my NHS results came back as ‘mixed growth’ or ‘no significant growth’, which basically left me with no treatment plan and I felt fobbed off; it was such a waste of everyone’s time.
The Lodestar machine identified the specific three bacteria immediately. I wish I’d come here sooner; it’s the first time I’ve had a definitive answer and I’ve felt empowered.
News & Insights
- Awards
- Clinical Studies
- Appointments
Llusern bags a hat-trick at ICS 2026.
Two abstracts published in The Journal of Urology.
Llusern announces changes to Exec team and new NED
Let's talk business
Llusern has its first product in-market that is focused on a diagnostic need and has a sustainable device-plus-consumables proposition.
To learn more about the company, Lodestar DX and the business opportunity, get in touch with the Llusern Scientific team.
